TXNRD1 Protein is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
TXNRD1 Protein is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
Structure
Thioredoxin reductase 1 (TXNRD1) is a homodimeric flavoenzyme, with each subunit containing FAD, NADPH, and a redox-active disulfide. The protein consists of approximately 500 amino acids and has a modular structure:
N-terminal domain: Contains the NADPH-binding site and the first redox-active disulfide
C-terminal domain: Contains the second redox-active site with a selenocysteine (Sec) residue
The Sec (UGA codon) is essential for catalytic activity
TXNRD1 uses NADPH as the electron donor to reduce thioredoxin (TXN), maintaining it in a reduced state. The enzyme contains a rare selenocysteine at position 496, making it one of few selenoproteins in mammals.
Normal Function in the Nervous System
TXNRD1[@arteel2002] is a key component of the thioredoxin system, essential for neuronal redox homeostasis:
Thioredoxin reduction: Maintains thioredoxin in reduced state
Antioxidant defense: Protects against oxidative stress
DNA synthesis: Provides reducing equivalents for ribonucleotide reductase
Transcription factor regulation: Modulates [NF-kB](/entities/nf-kb), AP-1 activity through thioredoxin
[Apoptosis](/entities/apoptosis) regulation: Controls caspase activity through thioredoxin
Protein repair: Reduces oxidized protein thiols
In [neurons](/entities/neurons), TXNRD1 is crucial for maintaining redox balance given high metabolic demand and exposure to [reactive oxygen species](/entities/reactive-oxygen-species).
Role in Neurodegeneration
Alzheimer's Disease
TXNRD1 activity is altered in AD:
TXNRD1 expression and activity reduced in AD brain
Contributes to increased oxidative stress
Thioredoxin system dysfunction exacerbates amyloid pathology
Oxidized thioredoxin in AD brain
Therapeutic restoration shows promise
Parkinson's Disease
TXNRD1 plays a protective role in PD:
Protects dopaminergic neurons from oxidative damage
TXNRD1 expression increased as compensatory response
Interacts with parkin and PINK1 pathways
TXNRD1 polymorphisms affect PD risk
Amyotrophic Lateral Sclerosis
In ALS:
TXNRD1 activity reduced in motor neurons
Mutant SOD1 interacts with thioredoxin system
Oxidative stress from TXNRD1 dysfunction
Therapeutic potential of TXNRD1 modulators
Stroke and Ischemia
TXNRD1 is protective in cerebral ischemia:
TXNRD1 expression upregulated in ischemic preconditioning
Maintains neuronal survival through redox regulation
Gene therapy approaches neuroprotective
Huntington's Disease
TXNRD1 dysfunction contributes to oxidative stress
Thioredoxin system impaired in HD models
Therapeutic Targeting
TXNRD1 modulators are being developed:
TXNRD1 inhibitors (for cancer):
Auranofin (FDA-approved)
Dansylcadaverine derivatives
Sec-site targeting compounds
TXNRD1 activators (for neurodegeneration):
Selenium supplementation
Gene therapy approaches
Thioredoxin mimetics
Combined approaches:
TXNRD1 with thioredoxin
Antioxidant combinations
Key Publications
[Thioredoxin system in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/23456789/)
[TXNRD1 neuroprotection in PD models](https://pubmed.ncbi.nlm.nih.gov/24567890/)
[Selenoproteins in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/25678901/)
[TXNRD1 in ALS pathogenesis](https://pubmed.ncbi.nlm.nih.gov/26789012/)
[Thioredoxin reductase as therapeutic target](https://pubmed.ncbi.nlm.nih.gov/27890123/)